Sequencer as a Service Global Market Report 2026

The sequencer as a service market size has grown rapidly in recent years. It will grow from $2.31 billion in 2025 to $2.76 billion in 2026 at a compound annual growth rate (CAGR) of 19.8%. The growth in the historic period can be attributed to rising demand for genomic research, limited access to in-house sequencing platforms, high cost of sequencing instruments, growth in personalized medicine initiatives, increasing collaborations between research institutes and sequencing providers.

The sequencer as a service market size is expected to see exponential growth in the next few years. It will grow to $5.73 billion in 2030 at a compound annual growth rate (CAGR) of 20%. The growth in the forecast period can be attributed to adoption of cloud-based sequencing solutions, demand for high-throughput sequencing services, integration of ai-driven bioinformatics analysis, expansion of clinical genomics applications, increasing outsourcing of sequencing services. Major trends in the forecast period include cloud-based sequencing services, automated sample preparation, integrated bioinformatics solutions, pay-per-use sequencing models, scalable genomic data management.

The rising prevalence of genetic disorders is projected to fuel the growth of the sequencer as a service market going forward. Genetic disorders refer to medical conditions caused by abnormalities in an individual's deoxyribonucleic acid, inherited from one or both parents or arising from new mutations. The prevalence of genetic disorders is increasing due to factors such as advancing parental age, as older parents have a higher risk of passing genetic mutations to their offspring. Sequencer as a service addresses genetic disorders by providing scalable, on-demand access to advanced DNA and RNA sequencing technologies, enabling early detection and accurate diagnosis. It reduces infrastructure and operational burdens for laboratories and healthcare providers by offering cloud-based data analysis and expert support, enhancing precision medicine outcomes and research efficiency. For example, in May 2024, according to the National Health Service, a UK-based government department, there are 17,000 individuals living with sickle cell disease, an inherited genetic blood disorder, with approximately 250 new cases diagnosed annually. Therefore, the increasing prevalence of genetic disorders is driving the growth of the sequencer as a service market.

Leading companies operating in the sequencer as a service market are focusing on integrating artificial intelligence-driven bioinformatics platforms, such as certified provider accreditation initiative, to enhance service quality, technical compliance, and standardized workflow efficiency across genomics and single-cell analysis applications. Certified provider accreditation initiative refers to a structured program in which an organization formally recognizes and authorizes external service providers or partners who meet predefined standards of technical expertise, operational quality, and compliance. For example, in July 2024, Parse Biosciences, a Seattle-based provider of single-cell sequencing solutions, launched its Certified Service Provider Program to broaden access to scalable single-cell analysis. The program enables researchers to collaborate with accredited providers such as SeqMatic and Eurofins Clinical Enterprise, who deliver end-to-end workflows including Evercode Whole Transcriptome, Evercode TCR, CRISPR Detect, Gene Capture, and Evercode BCR, capturing full-length BCR sequences alongside gene expression at high throughput. This initiative ensures expert sample handling, workflow standardization, and high-quality results making it ideal for both pilot studies and routine large-scale single-cell projects.

In February 2026, Swiss Rockets AG, a Switzerland-based life sciences venture builder, acquired Complete Genomics Inc. for an undisclosed amount. Through this acquisition, Swiss Rockets AG aims to strengthen its biotechnology development portfolio, accelerate innovation in precision medicine, and broaden global sequencing technology capabilities. Complete Genomics Inc. is a US-based genomics company engaged in a sequencer-as-a-service model, offering outsourced sequencing services alongside its proprietary DNBSEQ™ instruments.

Major companies operating in the sequencer as a service market are Admera Health, ArrayGen Technologies, BGI Genomics Co. Ltd., CD Genomics Inc., Element Biosciences, Eurofins Scientific SE, Gene by Gene, GENEWIZ Germany GmbH, Illumina Inc., Karkinos Healthcare, Lucigen, Macrogen Inc., MedGenome Labs Ltd., Novogene Co. Ltd., Quest Diagnostics, SeqMatic LLC, SeqWell, Strand Life Sciences Pvt. Ltd., Veritas Genetics, Yaazh Xenomics.

North America was the largest region in the sequencer as a service market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sequencer as a service market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sequencer as a service market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sequencer as a service market includes revenues earned by entities through on-demand genomic sequencing solutions, laboratory processing, transcriptome sequencing services, and cloud-based genomic data management services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sequencer as a service is a business model where genomic sequencing capabilities are provided on a contractual or pay-per-use basis instead of requiring in-house sequencing equipment. It allows organizations to access advanced DNA and RNA sequencing technologies, laboratory infrastructure, and bioinformatics analysis without large capital investments. This model reduces costs, improves scalability, and accelerates research, diagnostics, and innovation through end-to-end sequencing solutions from specialized providers.

The primary components of sequencer-as-a-service include software, hardware, and services. Software refers to platforms managing sequencing workflows, data analysis, and reporting for end-to-end genomics solutions. Service types include sample preparation, library preparation, sequencing execution, bioinformatics analysis, data storage and management, and integrated end-to-end sequencing services, deployed via cloud-based and on-premises modes. Applications include clinical diagnostics, oncology research, rare disease research, infectious disease surveillance, drug discovery and development, agrigenomics, forensic genomics, reproductive health testing, and personalized medicine research, serving hospitals and clinics, research institutes, pharmaceutical and biotechnology companies, academic institutions, and other end users.

Tariffs have affected the sequencer as a service market by increasing costs for importing high-throughput sequencing instruments, laboratory automation equipment, and data processing hardware. Segments such as hardware and integrated end-to-end sequencing services are most impacted, particularly in regions like North America and Europe reliant on imported advanced equipment. While tariffs have raised operational costs, they are encouraging local manufacturing of sequencing instruments and promoting investment in domestic service providers, ultimately supporting innovation and cost-efficient solutions.

The sequencer as a service market research report is one of a series of new reports that provides sequencer as a service market statistics, including sequencer as a service industry global market size, regional shares, competitors with a sequencer as a service market share, detailed sequencer as a service market segments, market trends and opportunities, and any further data you may need to thrive in the sequencer as a service industry. This sequencer as a service market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.